Last reviewed · How we verify

Strontium Ranelate + Ca/Vitamin-D

Medical University of Vienna · FDA-approved active Small molecule

Strontium ranelate promotes bone formation and reduces bone resorption, while calcium and vitamin D provide essential minerals and cofactors for bone mineralization and calcium homeostasis.

Strontium ranelate promotes bone formation and reduces bone resorption, while calcium and vitamin D provide essential minerals and cofactors for bone mineralization and calcium homeostasis. Used for Osteoporosis in postmenopausal women, Osteoporosis in men at high risk of fracture.

At a glance

Generic nameStrontium Ranelate + Ca/Vitamin-D
Also known asProtelos (r)
SponsorMedical University of Vienna
Drug classBone-active agent / Antiosteoporotic combination
TargetOsteoblasts and osteoclasts (non-receptor mediated); calcium-sensing receptor (vitamin D component)
ModalitySmall molecule
Therapeutic areaOrthopedics / Rheumatology
PhaseFDA-approved

Mechanism of action

Strontium ranelate acts as a dual-action agent that stimulates osteoblast differentiation and bone formation while simultaneously inhibiting osteoclast-mediated bone resorption. The addition of calcium and vitamin D enhances intestinal calcium absorption and provides the mineral substrate necessary for effective bone mineralization, creating a comprehensive approach to improving bone density and strength.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: